IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

被引:161
作者
Dubbink, H. J. [2 ]
Taal, W. [1 ]
van Marion, R. [2 ]
Kros, J. M. [2 ]
van Heuvel, I. [1 ]
Bromberg, J. E. [1 ]
Zonnenberg, B. A. [3 ]
Zonnenberg, C. B. L. [4 ]
Postma, T. J. [4 ]
Gijtenbeek, J. M. M. [5 ]
Boogerd, W. [6 ]
Groenendijk, F. H. [2 ,7 ]
Smitt, P. A. E. Sillevis [1 ]
Dinjens, W. N. M. [2 ]
van den Bent, M. J. [1 ]
机构
[1] Univ Med Ctr, Dr Daniel Den Hoed Canc Ctr, Erasmus MC, Dept Neurooncol Neurol, NL-3075 EA Rotterdam, Netherlands
[2] Univ Med Ctr, Josephine Nefkens Inst, Dept Pathol, NL-3075 EA Rotterdam, Netherlands
[3] Univ Med Ctr, Dept Internal Med, Utrecht, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands
[6] Netherlands Canc Inst, Dept Neurol, Amsterdam, Netherlands
[7] Univ Maastricht, Fac Hlth Med & Life Sci, Maastricht, Netherlands
关键词
TUMORS; GLIOMAS;
D O I
10.1212/WNL.0b013e3181c34ace
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-grade astrocytoma and whether these mutations predict outcome to specific treatment. Methods: We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy. Results: IDH1 mutations were present in 86% of the 49 progressive astrocytomas. No mutations in IDH2 were found. Presence of IDH1 mutations were early events and significantly improved overall survival (median survival 48 vs 98 months), but did not affect outcome of temozolomide treatment. Conclusion: These results indicate that IDH1 mutations identify a subgroup of gliomas with an improved survival, but are unrelated to the temozolomide response. Neurology (R) 2009; 73: 1792-1795
引用
收藏
页码:1792 / 1795
页数:4
相关论文
共 8 条
[1]   Analysis of the IDH1 codon 132 mutation in brain tumors [J].
Balss, Joerg ;
Meyer, Jochen ;
Mueller, Wolf ;
Korshunov, Andrey ;
Hartmann, Christian ;
von Deimling, Andreas .
ACTA NEUROPATHOLOGICA, 2008, 116 (06) :597-602
[2]   IDH1 Mutations at Residue p.R132 (IDH1R132) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors [J].
Bleeker, Fonnet E. ;
Lamba, Simona ;
Leenstra, Sieger ;
Troost, Dirk ;
Hulsebos, Theo ;
Vandertop, W. Peter ;
Frattini, Milo ;
Molinari, Francesca ;
Knowles, Margaret ;
Cerrato, Aniello ;
Rodolfo, Monica ;
Scarpa, Aldo ;
Felicioni, Lara ;
Buttitta, Fiamma ;
Malatesta, Sara ;
Marchetti, Antonio ;
Bardelli, Alberto .
HUMAN MUTATION, 2009, 30 (01) :7-11
[3]   1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment [J].
Kouwenhoven, Mathilde C. M. ;
Kros, Johan M. ;
French, Pim J. ;
Biemond-ter Stege, Elize M. ;
Graveland, Wilfried J. ;
Taphoorn, Martin J. B. ;
Brandes, Alba A. ;
van den Bent, Martin J. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2499-2503
[4]   RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].
MACDONALD, DR ;
CASCINO, TL ;
SCHOLD, SC ;
CAIRNCROSS, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280
[5]   An integrated genomic analysis of human glioblastoma Multiforme [J].
Parsons, D. Williams ;
Jones, Sian ;
Zhang, Xiaosong ;
Lin, Jimmy Cheng-Ho ;
Leary, Rebecca J. ;
Angenendt, Philipp ;
Mankoo, Parminder ;
Carter, Hannah ;
Siu, I-Mei ;
Gallia, Gary L. ;
Olivi, Alessandro ;
McLendon, Roger ;
Rasheed, B. Ahmed ;
Keir, Stephen ;
Nikolskaya, Tatiana ;
Nikolsky, Yuri ;
Busam, Dana A. ;
Tekleab, Hanna ;
Diaz, Luis A., Jr. ;
Hartigan, James ;
Smith, Doug R. ;
Strausberg, Robert L. ;
Marie, Suely Kazue Nagahashi ;
Shinjo, Sueli Mieko Oba ;
Yan, Hai ;
Riggins, Gregory J. ;
Bigner, Darell D. ;
Karchin, Rachel ;
Papadopoulos, Nick ;
Parmigiani, Giovanni ;
Vogelstein, Bert ;
Velculescu, Victor E. ;
Kinzler, Kenneth W. .
SCIENCE, 2008, 321 (5897) :1807-1812
[6]   Determination of the molecular relationship between multiple tumors within one patient is of clinical importance [J].
van der Sijp, JRM ;
van Meerbeeck, JPAM ;
Moat, APWM ;
Zondervan, PE ;
Sleddens, HFBM ;
van Geel, AN ;
Eggermont, AMM ;
Dinjens, WNM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :1105-1114
[7]  
WATANABE T, 2009, AM J PATHOL IN PRESS
[8]   IDH1 and IDH2 Mutations in Gliomas [J].
Yan, Hai ;
Parsons, D. Williams ;
Jin, Genglin ;
McLendon, Roger ;
Rasheed, B. Ahmed ;
Yuan, Weishi ;
Kos, Ivan ;
Batinic-Haberle, Ines ;
Jones, Sian ;
Riggins, Gregory J. ;
Friedman, Henry ;
Friedman, Allan ;
Reardon, David ;
Herndon, James ;
Kinzler, Kenneth W. ;
Velculescu, Victor E. ;
Vogelstein, Bert ;
Bigner, Darell D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08) :765-773